Cervical Cancer kills approximately 275,000 women every year. Around 500,000 cases are reported worldwide. Each year, around 3,100 women are diagnosed with this cancer in the UK and about 12,000 women in the United States. Studies say, all women are at risk for cervical cancer and it occurs most often in women aged less than 35 years. The global estimated data for cervical cancer market is valued at $1.8 billion, which would further grow to $4.1 billion by 2016 at a Compound Annual Growth Rate (CAGR) of 11.9% between the years 2009 to 2016.
Cervical cancer is an unusual type of cancer that develops in a woman’s cervix. Cervix being the narrower and lower part of the uterus (or womb)/the entrance to the womb is an opening that connects to the uterus to the vagina. Cervical cancer is a malignant that starts in the cells of the cervix.
Most of the cervical cancer in women is caused due to a virus called HPV or human papillomavirus. HPV can get into the body during a sexual contact with another person who has it. Although there are many types of HPV virus, not all cause cervical cancer. Cervical cancer is highly preventable in most parts of the Western countries as vaccine and screening tests are readily available to prevent HPV infections.
ResearchMoz market research reports provide the most up-to-date information about the global cervical cancer market. It covers emerging therapies for cervical cancer in different clinical development stages including both early and late stage clinical trials. Most importantly it is an essential source of information and analysis on the global cervical cancer market. The report identifies various factors and provides insight on driving and shaping the market, and key information on significant shifts in the market positioning of the existing market leaders. For more such information, speak to a ResearchMoz Research Coordinator today.